Burney Co. Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Burney Co. boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 20.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,840 shares of the specialty pharmaceutical company's stock after buying an additional 4,079 shares during the quarter. Burney Co.'s holdings in Jazz Pharmaceuticals were worth $2,936,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in JAZZ. Itau Unibanco Holding S.A. bought a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock valued at $46,000 after purchasing an additional 121 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 577.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock worth $92,000 after buying an additional 704 shares during the period. Finally, Versant Capital Management Inc grew its position in shares of Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company's stock worth $119,000 after buying an additional 350 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Down 0.5 %

Jazz Pharmaceuticals stock traded down $0.62 during midday trading on Thursday, reaching $122.62. The company's stock had a trading volume of 357,287 shares, compared to its average volume of 490,529. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17. The stock has a market capitalization of $7.41 billion, a P/E ratio of 17.27, a PEG ratio of 0.88 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock's 50-day simple moving average is $122.83 and its 200-day simple moving average is $114.50.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares of the company's stock, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 8,253 shares of company stock valued at $1,001,434 in the last three months. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. TD Cowen reduced their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a report on Thursday, November 7th. Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th. Needham & Company LLC reissued a "buy" rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.